CD22 and acute lymphoblastic leukemia: A phase I study [36] revealed that anti-CD22 CAR T cells could mediate disease remission in B-ALL that is naive or resistant to anti-CD19 CAR T cell immunotherapy, with complete remission observed in 5/5 patients with CD19dim/CD19− B-ALL.